Search the Newsreel

Chemomab Therapeutics Ltd. Revenue Breakdown – NASDAQ:CMMB

This article provides financial information for Chemomab Therapeutics Ltd. (NASDAQ: CMMB) on TradingView. It indicates that the market is closed with no recent trades. The content focuses on an overview of financial data, segments, and other fundamental statistics for the company.

AbbVie (ABBV) Could Be 3% Undervalued Following Epcoritamab Trial Setback

Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Genmab and AbbVie (ABBV) recently clarified that the U.S. portion of the Phase 3 EPCORE DLBCL-1 trial for epcoritamab did not meet its …

Price to earnings forward of AgomAb Therapeutics NV – NASDAQ:AGMB

This article provides the "Price to earnings forward" value for AgomAb Therapeutics NV (NASDAQ: AGMB). It shows that for the specified period, the value is listed as "No trades." The information is presented within a financial data context.

CMMB|Chemomab Therapeutics Ltd|Price:1.800|Chg%:+0.050

This article provides a stock score and comprehensive analysis of Chemomab Therapeutics Ltd (CMMB) from TradingKey. It details how TradingKey generates its stock scores across six dimensions: financial health, company profile, earnings forecasts, price momentum, institutional confidence, and risk assessment. The article states that …

AgomAb Therapeutics NV Revenue Breakdown – NASDAQ:AGMB

This article displays the revenue breakdown for AgomAb Therapeutics NV, trading under the NASDAQ symbol AGMB. It provides a financial overview of the company, focusing on fundamentals, statements, statistics, dividends, earnings, and segment performance. The content includes links to various financial data and tools …

Genmab A/S Revenue Breakdown – FWB:GE9

Genmab A/S (FWB:GE9) generated 3.17 billion EUR in revenue last year, with its Antibody Therapeutics segment contributing the most at 3.29 billion EUR. The largest regional contribution came from Denmark, accounting for 2.94 billion EUR. The article provides a high-level overview of the company's …

Gladstone Land Corp. Revenue Breakdown – FWB:3L4

Gladstone Land Corp. (FWB:3L4) generated €75.21 million in revenue last year, primarily from its Fixed Lease Payments segment which contributed €43.58 million. This represents an increase from the previous year's total revenue of €71.44 million, with the United States being the sole geographical contributor. …

Genmab (GMAB) Receives a Hold from Morgan Stanley

Morgan Stanley analyst Judah Frommer assigned a Hold rating to Genmab (GMAB) with a price target of $33.00. This follows a recent upgrade to Buy from Hold by TD Cowen. Genmab reported quarterly revenue of $899.32 million and a net profit of $53.2 million, …

Genmab, AbbVie Clarify Epcoritamab Phase 3 Trial Missed Primary Endpoint

Genmab and AbbVie issued a clarification regarding their Phase 3 EPCORE DLBCL-1 trial, stating that overall survival was the sole U.S. primary endpoint and it was not met. This clarification was deemed necessary due to interpretive ambiguity in earlier disclosures, highlighting the complexities of …

Genmab & AbbVie's Epcoritamab Fails To Meet Primary Goal In Phase 3 EPCORE DLBCL-1 Trial

(RTTNews) - Genmab A/S (GMAB) and AbbVie Inc. (ABBV) on Thursday announced that the Phase 3 EPCORE DLBCL-1 trial evaluating Epcoritamab in adults with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) failed to meet its U.S. primary endpoint of overall survival (OS). …

Genmab, AbbVie Say Lymphoma Drug Failed to Meet Primary Endpoint in Phase 3 Trial

Genmab and AbbVie announced that their lymphoma drug, epcoritamab, did not meet the primary endpoint in a Phase 3 clinical trial. The trial aimed to evaluate the drug's efficacy in patients with diffuse large B-cell lymphoma (DLBCL). This outcome is a setback for the …

Genmab stock trades steadily as investors weigh recent earnings and oncology pipeline momentum

Genmab A/S stock is maintaining a steady trade as investors analyze the company's recent strong revenue growth from its antibody-driven oncology treatments and its positive profitability trends. The biotechnology company balances its established commercial products with significant investment in its pipeline of clinical-stage oncology …

Genmab and AbbVie Provide Clarification on Phase 3 EPCORE® DLBCL-1 Trial Evaluating Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)

Genmab and AbbVie clarified that overall survival (OS) was the sole U.S. primary endpoint for the Phase 3 EPCORE DLBCL-1 trial, which unfortunately did not meet this endpoint, indicating no statistically significant improvement in OS. The study evaluated epcoritamab in adults with relapsed or …

B.Riley initiates Agomab Therapeutics stock with buy rating

B.Riley has initiated coverage on Agomab Therapeutics (NASDAQ:AGMB) with a "buy" rating and a price target of $34.00, suggesting a nearly 200% upside from its current trading price of $11.60. The firm highlights Agomab's focus on developing organ-restricted small-molecule inhibitors for fibrosis, particularly in …

Mitchells & Butlers says hot weather hit demand at carveries and steakhouses

Mitchells & Butlers (M&B) has revealed a slump in food sales in recent months after hot summer weather dented demand for steak dinners and carvery lunches. The pub and bar giant saw shares slide on Thursday as a result. The hospitality operator said sales …

Mitchells & Butlers maintains growth despite weather-related pressure on food-led venues

GMAB Upgraded by TD Cowen -- Price Target Raised to $43.00

TD Cowen has upgraded Genmab (GMAB) from Hold to Buy, significantly increasing its price target from $32.00 to $43.00. This upgrade signals a positive outlook on the biopharmaceutical company's growth and market position. GuruFocus assesses GMAB as 17.7% undervalued with a strong GF Score …

TD Cowen upgrades Genmab to buy (hold) - BN

TD Cowen has upgraded Genmab (GMAB) stock from a "Hold" to a "Buy" rating. The firm also increased its price target for Genmab shares to $43 from $32. This upgrade reflects a more optimistic outlook on the biotechnology company's future performance.

TD Cowen upgrades Genmab stock rating on drug pipeline confidence

TD Cowen upgraded Genmab A/S to Buy from Hold and raised its price target to $43.00 due to confidence in the company's drug pipeline, specifically Epkinly, Rina-S, and peto, which are expected to offset the Darzalex patent cliff. The firm believes the stock is …

Genmab stock holds after recent earnings and pipeline updates

Genmab's stock performance reflects its latest financial results and pipeline developments, with the company reporting increased revenue and operating profit for 2025. The company's cash generation and improved operating margin highlight its financial health, while its valuation remains heavily linked to its antibody pipeline …

Biotech Stocks At 52-Week Highs - XNCR, COAG, MNPR, SOPH, ACRS

(RTTNews) - The following biotech stocks reached a 52-week high on July 20, 2026, driven by key catalysts such as upcoming clinical trial launches and the prospective release of data from these studies. Xencor Inc. (XNCR) Xencor is a clinical-stage biopharmaceutical company currently advancing …

Mitchells & Butlers Reports Executive Share Incentive Plan Purchases

Goldman Sachs raises Genmab price target to 2,350 Danish kroner (2,300), reiterates buy - BN

Goldman Sachs has increased its price target for Genmab A/S to 2,350 Danish kroner from the previous 2,300, while maintaining a "buy" rating on the stock. This update reflects the firm's continued confidence in the biotechnology company specializing in cancer treatments and other therapeutic …

Hemab Therapeutics (NASDAQ:COAG) Hits New 12-Month High - What's Next?

Chemomab Therapeutics (CMMB) Q4 2025 earnings summary

Chemomab Therapeutics reported its Q4 2025 earnings, highlighting a positive FDA End-of-Phase 2 meeting for nebokitug in PSC, paving the way for a single Phase 3 trial. The company also announced strong financial management with a cash runway expected through Q1 2027 and reduced …

Hemab Therapeutics Holdings (NasdaqGS:COAG) Stock Forecast & Analyst Predictions

Hemab Therapeutics Holdings (NasdaqGS:COAG) is projected to experience a 14.6% annual decline in earnings, while revenue is expected to grow by 74.3% per year. The company's lead asset, sutacimig, is moving into a Phase 3 trial for Glanzmann thrombasthenia, supported by strong Phase 2 …

Chemomab Therapeutics (CMMB) H.C. Wainwright 27th Annual Global Investment Conference summary

Chemomab Therapeutics (CMMB) presented positive Phase II results for nebokitug, a potential first-in-class treatment for primary sclerosing cholangitis (PSC), at the H.C. Wainwright 27th Annual Global Investment Conference. The drug met safety and efficacy endpoints, leading to FDA alignment for a single pivotal Phase …

GLADSTONE LAND CORP 6.00% CUM REDEEMABLE PFD STK SER B To Go Ex-Dividend On July 24th, 2026 With 0.125 USD Dividend Per Share

GLADSTONE LAND CORP 6.00% CUM REDEEMABLE PFD STK SER B (NASDAQ:LANDP) is scheduled to go ex-dividend on July 24th, 2026. Shareholders of record will receive a dividend of 0.125 USD per share. This announcement indicates an upcoming dividend payment for investors in LANDP.

Hemab Therapeutics Holdings, Inc. (NASDAQ:COAG) Receives Average Rating of "Moderate Buy" from Brokerages

Hemab Therapeutics (NASDAQ:COAG) Shares Up 5.5% - Here's What Happened

HBM boosts Chemomab Therapeutics Ltd. (CMMB) stake amid Scipher merger plan

HBM Healthcare Investments (Cayman) Ltd. has significantly increased its beneficial ownership in Chemomab Therapeutics Ltd. (CMMB) to approximately 12.5%, amidst Chemomab's planned merger with Scipher Medicine Corporation. HBM will vote its shares in favor of the merger, which includes contingent value rights for current …

Gladstone Land authorizes $55M preferred stock buyback

Gladstone Land Corporation has announced a $55 million share repurchase program for its preferred stock, targeting up to $20 million of Series B and $35 million of Series C shares. The company believes repurchasing its undervalued preferred stock is a favorable strategic use of …

Genmab Announces Net Sales of DARZALEX® (daratumumab) for Second Quarter of 2026

Genmab A/S announced that worldwide net trade sales of its drug DARZALEX (daratumumab), including the subcutaneous product DARZALEX FASPRO®, totaled USD 4,207 million in the second quarter of 2026. The sales were split with USD 2,435 million in the U.S. and USD 1,772 million …

Is AgomAB Therapeutics NV (AGMB) Stock a Biotech Opportunity With Targeted Tissue Therapy Potential?

AgomAb Therapeutics: High Risk, High Reward Stock (NASDAQ:AGMB)

Analyst Estimates: Here's What Brokers Think Of Genmab A/S (CPH:GMAB) After Its First-Quarter Report